Guillain–Barré syndrome following coronavirus disease vaccine: First report from Nepal
ChAdOx1 nCoV-19 is an effective and well-tolerated coronavirus disease 2019 vaccine. However, rare cases of serious adverse events have been reported with it. We report a patient who did not have active or prior coronavirus disease 2019 infection, who developed Guillain–Barré syndrome 7 days followi...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-05-01
|
| Series: | SAGE Open Medical Case Reports |
| Online Access: | https://doi.org/10.1177/2050313X221100876 |
| _version_ | 1811338977350778880 |
|---|---|
| author | Prajjwol Luitel Bibek Poudel Devansh Upadhyay Sujan Paudel Nishan Tiwari Bikram Prasad Gajurel Ragesh Karn Reema Rajbhandari Aashish Shrestha Niraj Gautam Rajeev Ojha |
| author_facet | Prajjwol Luitel Bibek Poudel Devansh Upadhyay Sujan Paudel Nishan Tiwari Bikram Prasad Gajurel Ragesh Karn Reema Rajbhandari Aashish Shrestha Niraj Gautam Rajeev Ojha |
| author_sort | Prajjwol Luitel |
| collection | DOAJ |
| description | ChAdOx1 nCoV-19 is an effective and well-tolerated coronavirus disease 2019 vaccine. However, rare cases of serious adverse events have been reported with it. We report a patient who did not have active or prior coronavirus disease 2019 infection, who developed Guillain–Barré syndrome 7 days following the first dose of ChAdOx1 nCoV-19 vaccination. He was treated with intravenous immunoglobulin, with stabilization of the disease. Proper monitoring and prompt reporting of such cases are required to ensure the safety of the vaccine. |
| first_indexed | 2024-04-13T18:18:24Z |
| format | Article |
| id | doaj.art-f183a7dac63949c799a8897d15d8c99d |
| institution | Directory Open Access Journal |
| issn | 2050-313X |
| language | English |
| last_indexed | 2024-04-13T18:18:24Z |
| publishDate | 2022-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | SAGE Open Medical Case Reports |
| spelling | doaj.art-f183a7dac63949c799a8897d15d8c99d2022-12-22T02:35:36ZengSAGE PublishingSAGE Open Medical Case Reports2050-313X2022-05-011010.1177/2050313X221100876Guillain–Barré syndrome following coronavirus disease vaccine: First report from NepalPrajjwol Luitel0Bibek Poudel1Devansh Upadhyay2Sujan Paudel3Nishan Tiwari4Bikram Prasad Gajurel5Ragesh Karn6Reema Rajbhandari7Aashish Shrestha8Niraj Gautam9Rajeev Ojha10Tribhuvan University Institute of Medicine, Kathmandu, NepalTribhuvan University Institute of Medicine, Kathmandu, NepalTribhuvan University Institute of Medicine, Kathmandu, NepalTribhuvan University Institute of Medicine, Kathmandu, NepalTribhuvan University Institute of Medicine, Kathmandu, NepalDepartment of Neurology, Tribhuvan University Institute of Medicine, Kathmandu, NepalDepartment of Neurology, Tribhuvan University Institute of Medicine, Kathmandu, NepalDepartment of Neurology, Tribhuvan University Institute of Medicine, Kathmandu, NepalDepartment of Neurology, Tribhuvan University Institute of Medicine, Kathmandu, NepalDepartment of Neurology, Tribhuvan University Institute of Medicine, Kathmandu, NepalDepartment of Neurology, Tribhuvan University Institute of Medicine, Kathmandu, NepalChAdOx1 nCoV-19 is an effective and well-tolerated coronavirus disease 2019 vaccine. However, rare cases of serious adverse events have been reported with it. We report a patient who did not have active or prior coronavirus disease 2019 infection, who developed Guillain–Barré syndrome 7 days following the first dose of ChAdOx1 nCoV-19 vaccination. He was treated with intravenous immunoglobulin, with stabilization of the disease. Proper monitoring and prompt reporting of such cases are required to ensure the safety of the vaccine.https://doi.org/10.1177/2050313X221100876 |
| spellingShingle | Prajjwol Luitel Bibek Poudel Devansh Upadhyay Sujan Paudel Nishan Tiwari Bikram Prasad Gajurel Ragesh Karn Reema Rajbhandari Aashish Shrestha Niraj Gautam Rajeev Ojha Guillain–Barré syndrome following coronavirus disease vaccine: First report from Nepal SAGE Open Medical Case Reports |
| title | Guillain–Barré syndrome following coronavirus disease vaccine: First report from Nepal |
| title_full | Guillain–Barré syndrome following coronavirus disease vaccine: First report from Nepal |
| title_fullStr | Guillain–Barré syndrome following coronavirus disease vaccine: First report from Nepal |
| title_full_unstemmed | Guillain–Barré syndrome following coronavirus disease vaccine: First report from Nepal |
| title_short | Guillain–Barré syndrome following coronavirus disease vaccine: First report from Nepal |
| title_sort | guillain barre syndrome following coronavirus disease vaccine first report from nepal |
| url | https://doi.org/10.1177/2050313X221100876 |
| work_keys_str_mv | AT prajjwolluitel guillainbarresyndromefollowingcoronavirusdiseasevaccinefirstreportfromnepal AT bibekpoudel guillainbarresyndromefollowingcoronavirusdiseasevaccinefirstreportfromnepal AT devanshupadhyay guillainbarresyndromefollowingcoronavirusdiseasevaccinefirstreportfromnepal AT sujanpaudel guillainbarresyndromefollowingcoronavirusdiseasevaccinefirstreportfromnepal AT nishantiwari guillainbarresyndromefollowingcoronavirusdiseasevaccinefirstreportfromnepal AT bikramprasadgajurel guillainbarresyndromefollowingcoronavirusdiseasevaccinefirstreportfromnepal AT rageshkarn guillainbarresyndromefollowingcoronavirusdiseasevaccinefirstreportfromnepal AT reemarajbhandari guillainbarresyndromefollowingcoronavirusdiseasevaccinefirstreportfromnepal AT aashishshrestha guillainbarresyndromefollowingcoronavirusdiseasevaccinefirstreportfromnepal AT nirajgautam guillainbarresyndromefollowingcoronavirusdiseasevaccinefirstreportfromnepal AT rajeevojha guillainbarresyndromefollowingcoronavirusdiseasevaccinefirstreportfromnepal |